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ABSTRACT
Gestational diabetes (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during preg-
nancy. Two major metabolic disorders: insulin resistance and β-cells dysfunction, play currently major role in pathogenesis 
of GDM. Adipose tissue is an organ involved in the production of adipokines, which have various influence on metabolism 
of glucose and lipids. Visfatin is an adipokine mainly produced and secreted by the fat tissue. It exerts an insulin-like effect 
by binding to the insulin receptor-1 and have hypoglycemic effect. Visfatin appears to be an important factor in the patho-
physiology of GDM. The aim of this article is to review the literature concerning the relationship between the adipokine 
mentioned above and GDM, and to clarify its role in the pathophysiology of GDM.
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INTRODUCTION
There has been a significant increase in obesity preva-
lence in the last 40 years, both in well-developed regions 
and in developing countries. The great interest and public 
health involvement is focused on the association between 
obesity and insulin resistance. Over the past few decades, 
the increasing number of over-weighted or obese women in 
reproductive age is observed. Maternal obesity and insulin re-
sistance are well-known, short- and long-term risk factors for 
poor perinatal outcome in the mother and fetus. Gestational 
Diabetes (GDM) is a carbohydrate intolerance first recognized 
in the course of pregnancy. Approximately 2-10% of all preg-
nant women are affected by the GDM [1]. So far, a variety of 
risk factors associated with etiology of GDM have been iden-
tified, including previous history of GDM, impaired glucose 
tolerance, ethnicity, family history of GDM or type 2 diabe-
tes (T2DM), advanced maternal age, history of macrosomic 
neonate delivery, stillbirth or neonate with a congenital de-
fect; hypertension, polycystic ovary syndrome, metabolic 
syndrome, obesity or high parity [2]. Although a remission 
of glucose intolerance is a frequent finding after delivery, 
patients with a history of gestational diabetes have a high 
risk of developing diabetes later in life, ranging from 17% to 
more than 50% risk depending on the population studied and 
the follow-up period [3]. Whereas, their offspring are more 
likely to be obese, affected by impaired glucose intolerance, 
develop T2DM or hypertension and cardiovascular diseases 
in early adulthood [4]. The development of GDM is believed 
to be the result of B-cell dysfunction due to increased insulin 
resistance associated with the physiological effects of pla-
cental hormones. Metabolic disturbances in women with 
GDM include reduced insulin secretion and increased insulin 
resistance, which are typically associated with overweight or 
obesity [5]. It is well-know that insulin sensitivity decreases, 
beginning in midpregnancy, to reach the insulin resistance 
observed in T2DM. Despite this physiological resistance, most 
women remain normoglycemic throughout pregnancy be-
cause of adequate B-cell compensation. GDM develops when 
insulin resistance (IR) is excessive, B-cell compensation is 
inadequate or its function decreases [3].
Adipocytokines
Maternal adiposity is an important modifiable risk fac-
tor for the development of GDM [6]. The adipose tissue is 
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involved in energy storage and also functions as an endo-
crine organ [7]. Adipocytokines are the bioactive proteins 
produced by adipose tissue, which have been recently im-
plicated in mediating insulin resistance (IR). It has been 
suggested that the hormones produced by the placenta 
and cytokines secreted by adipose tissues are related to 
the development of IR during pregnancy and therefore are 
possibly playing an important role in the pathogenesis of 
GDM [8]. As soluble factors secreted into the bloodstream, 
adipokines take part in various metabolic processes includ-
ing insulin sensitivity, insulin secretion, appetite control, 
fat distribution, energy expenditure, inflammation, regula-
tion of adipogenesis and chemoattraction of immune cells 
into adipose tissue. Essentially, there are direct and indirect 
mechanisms by which altered adipokine secretion may con-
tribute to alterations in glucose homoeostasis in pregnancy, 
eventually causing GDM. Direct mechanisms include a role 
of adipokines in the regulation of insulin secretion and 
insulin sensitivity, both at the level of the whole organism 
and in the liver, brain, muscle and other tissues. Indirect 
mechanisms are mainly related to its role in inflammation, 
adipose tissue accumulation and adverse fat distribution, 
which subsequently affect glucose metabolism [9].
Visfatin
Visfatin, also known as pre-B cell colony-enhancing 
factor (PBEF) or nicotinamide phosphoribosyltransferase 
(NAMPT), is a 52 kDa protein produced mainly by the visceral 
adipose tissue in both human and mice. The gene for visfatin 
is located on the long arm of chromosome 7 (7q22.2) [10]. 
NAMPT is also expressed in human placenta although its ex-
pression is signiﬁcantly lower than in subcutaneous adipose 
tissue and visceral adipose tissue. Visfatin is expressed in 
fetal membranes, myometrium, bone marrow, liver, muscle, 
heart, lung, kidney, macrophages, neutrophils. It is also 
secreted into breast milk. Though the role of visfatin in hu-
man organism is controversial, it is known this adipokine is 
involved in regulation of energy homeostasis the pathogen-
esis of GDM. For instance, exposing adipocytes to glucose 
in vitro leads to the secretion of NAMPT. The secretion of 
visfatin by adipocytes in humans is influenced by glycemia 
[11, 12]. Obesity is also associated with increased circulating 
concentration of NAMPT. NAMPT exerts an insulin-like effect 
by binding to the insulin receptor-1. Thus, visfatin causes 
hypoglycemia through a combined mechanism involving 
the reduction of glycogenolysis in hepatocytes, stimulation 
of glucose utilization in adipocytes and myocytes in down-
stream signalling [13]. According to recent evidence, visfatin 
affects glucose homoeostasis by affecting B-cell function 
and the regulation of genes related to oxidative stress, the 
inﬂammatory response and the circadian rhythm. Moreover, 
circulating NAMPT concentrations are increased in patients 
with BMI above 30 and with type 2 diabetes, metabolic 
syndrome or cardiovascular disease [14].
NAMPT and GDM
There is almost an equal number of studies on circulat-
ing maternal visfatin concentrations presenting up-regu-
lation [15–19], down-regulation [20–23] as well as no influ-
ence on GDM development, as compared to the control 
group [24]. First studies on the relationship between the 
concentrations of NAMPT and prevalence of GDM were 
reported 10 years ago. Kim et al, in the diabetic rat model, 
demonstrated that central visfatin improved glucose toler-
ance by increasing insulin secretion and insulin sensitivity 
at euglycemia, through the hypothalamic mechanism. It is 
hypothesized that NAMPT may act as a positive modulator of 
glucose homeostasis by delivering the hypothalamic signals 
into the peripheries [25]. Visfatin concentration changes 
after an oral glucose tolerance test (OGTT) in physiologi-
cal pregnancies and this increase correlates with blood 
glucose, blood fat and insulin resistance. In vivo studies in 
humans demonstrated that hyperglycemia increases circu-
lating visfatin concentrations what assumed that the same 
mechanism occurs during pregnancy [12]. Ferreira et al. 
found an increased plasma visfatin level in the first trimester 
of pregnancy in women who developed GDM, what may 
suggest that NAMPT could be a potential biomarker for 
predicting GDM [26]. Lewandowski et al. have reported 
that impairment of glucose tolerance was accompanied by 
an increase in fasting visfatin. They also demonstrated a sig-
nificant correlation between NAMPT and fasting insulin and 
HOMA in GDM women in the third trimester of pregnancy 
[17]. Krzyżanowska et al. proved that visfatin is elevated 
substantially in women with GDM during the course of 
pregnancy and after delivery. They showed no association 
neither with insulin nor with leptin, fasting plasma glucose, 
plasma insulin, IR or BMI [16]. Zhaoxia et al. reported that 
pre-delivery serum visfatin and HOMA-IR were significantly 
higher than in the control group [18]. They also found posi-
tive correlation between BMI, excessive pregnancy weight 
gain in the GDM and increased visfatin levels. Morgan et al. 
proved a selective increase in NAMPT gene expression in 
pregnant women compared to the lean ones [27]. Coskun et 
al. compared plasma visfatin levels in three groups which in-
cluded women suffering from pre-gestational diabetes. They 
reported higher concentrations of visfatin in women with 
GDM as well as with PGDM [28]. Kaygusuz et al. proved 
that serum visfatin concentration is significantly higher in 
GDM and is correlated with ferritin levels [29]. Gorkem et al, 
did not find any difference in visfatin serum levels among 
healthy pregnant and the ones with GDM [30].
In the study designed by Chan et al., lower visfatin levels 
in women of Chinese origin with GDM was reported [20]. 
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Akturk et al. compared the relationship between visfatin and 
blood lipids in the GDM and normoglycemic women in the 
late-pregnancy. According to their studies, plasma visfatin 
levels were significantly decreased in pregnant women with 
GDM in comparison to the healthy group [21]. In Rezvan et 
al. research, plasma NAMPT concentrations were lower in 
patients with GDM and correlated to glycated haemoglo-
bin [22]. Telejko et al. showed that circulating visfatin was 
significantly lower in the GDM than in the NGT subjects 
at term, although no differences in mRNA expression in 
fat and placental tissues [23]. On the other hand Park et 
al. found that low visfatin and adiponectin, high proges-
terone levels in the circulation and increased energy and 
saturated fat intakes were common risk factors for GDM and 
pregnancy outcome such as large for gestational age neo-
nates [31]. Feng et al. in the trial on mouse islets, found that 
over-expression of NAMPT increased glucose-stimulated 
insulin secretion and increased beta cell expansion through 
augmentation of beta cell proliferation, without affecting 
beta cell apoptosis. They proved that NAMPT may enhance 
expansion of beta cell mass during pregnancy. Inadequate 
NAMPT may contribute to the development of GDM partially 
through reduced beta cell expansion in the gestational 
period [32]. According to Szamatowicz et al. serum visfatin 
concentrations are elevated in pregnant women, irrespec-
tively of their glucose tolerance status which is supposed 
to be caused by an additional secretion of visfatin from the 
placenta [33]. Finally, in the study that came from our Cen-
tre, by Iciek et al., we studied the possible role of placental 
visfatin/nicotinamide phosphoribosyltransferase (NAMPT) 
in fetal development in type 1 diabetic pregnancies (T1DM), 
the possible role of placental visfatin in fetal macrosomia. We 
demonstrated the lowest expression of placental NAMPT in 
women who delivered neonates with birth weight > 4000 g. 
The highest placental NAMPT expression was found in the 
women who delivered small (SGA) and appropriate (AGA) 
for gestational age newborns. There was also significant 
negative correlation between placental NAMPT expression 
and metabolic status in the 3rd trimester of pregnancy in 
T1DM LGA group, defined as long-term glycemic control 
— 3rd trimester HbA1C. We concluded that the low placen-
tal NAMPT expression and poor metabolic control in the 3rd 
trimester of pregnancy may have a role in stimulating fetal 
overgrowth in T1DM pregnancy [34].
CONCLUSIONS 
The clinical and public health aspect of gestational dia-
betes mellitus (GDM) is widely debated due to its increasing 
incidence, the resulting negative economic impact, and 
the potential for severe  GDM-related pregnancy compli-
cations. Unfortunately, effective  prevention  strategies in 
this area are still lacking, and controversies exist regarding 
diagnosis and management of this form of diabetes. Uni-
versal oral glucose tolerance-based screening is employed 
to identify pregnant women with GDM, as treatment of 
this condition decreases the risk of associated complica-
tions. A simple and accurate blood test, which identifies 
women at low or high risk for GDM in the first trimester, 
would have the potential to decrease costs and improve 
outcomes through prevention or treatment. Due to its mul-
tiple roles NAMPT has been implicated in a wide range 
of human diseases. Despite the vast number of studies 
reporting the role of visfatin and other adipocytokines in 
the pathogenesis of GDM, interpretation of results is dif-
ficult because of numerous limitations. First, the diagnostic 
criteria for GDM vary greatly. Second, the gestational age 
at the study times ranges from early first trimester to late 
third trimester. Third, differences in assay methods, small 
sample size and an absence of the adjustment of the levels 
on the possible confounders are another cause of heterog-
enous results. Obesity is accompanied by altered secretion 
of adipokines from adipose tissue [35]. GDM is a highly 
complexed process involving multiple factors. Mothers with 
preeclampsia or GDM were found to have both higher and 
lower circulating levels of visfatin in comparison with moth-
ers without pregnancy complications. The identification, as 
well as the determination of the molecular mechanisms by 
which these factors participate in the pathophysiology of 
GDM is currently an important challenge. Most importantly, 
an understanding of threatening risks provides an oppor-
tunity for prevention. Visfatin and its insulin-like effect may 
play an important role in pregnancy, it is likely to have 
protective effect of providing an additional response to 
elevated glucose levels during pregnancy. Beyond doubt, 
further investigation will be required to more fully deter-
mine the association between visfatin levels, glucose and 
blood lipids. Additionally, further characterization of the 
mechanism of visfatin expression, regulation, and secretion 
in placental tissue and adipocytes will be required in order 
to develop a complete understanding of the relationship 
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